{"title":"急诊单位医护人员第三剂COVID-19疫苗接种后体液反应评价","authors":"Abror Irsan, Mardhia Mardhia, Ambar Rialita","doi":"10.24853/mmj.3.1.27-32","DOIUrl":null,"url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an emerging disease that has become pandemic. Healthcare workers are vulnerable persons due to SARS-CoV-2 infection. Healthcare workers are a government priority in the COVID-19 vaccine program. Antibody titer evaluation to healthcare workers as the first liner is essential due to the risk of the job. Purposes: The study aims to assess IgG antibody humoral response in healthcare workers in the emergency unit of Anton Soedjarwo Hospital, Pontianak, before and after the third dose of the COVID-19 vaccine. Methods: This study was a descriptive study with a cohort method. Twenty-two healthcare workers in the Emergency Unit in Anton Soedjarwo Hospital, Pontianak, participated in the study. Three ml venous blood samples were collected from the participants in two periods to quantify IgG antibody titer. The first period was before the third dose of the COVID-19 vaccine, and the second period was one month after the third dose of the COVID-19 vaccine. Chemiluminescent Microparticle Immunoassay (CMIA) methods were used to quantification IgG antibodies against spike-receptor binding domain (S-RBD) protein of SARS-CoV-2 Results: One month before the third dose of the COVID-19 vaccine, the majority of IgG antibodies show seropositivity (90.91%), with most on range 50-10,000 AU/ml (54.55%). Two participants (9.09%) show IgG antibodies less than 50 AU/ml (seronegative). One month after the third vaccination dose, all participants (100%) elicit IgG antibodies. Based on the comparison of IgG antibody titer before and after the third dose of the vaccine, the majority (68.18%) showed increasing the IgG antibody titer after the third vaccine. Conclusion: The third dose vaccine might effectively elevate immune response to SARS-CoV-2 infection.","PeriodicalId":32215,"journal":{"name":"Journal of Muhammadiyah Medical Laboratory Technologist","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Evaluation of Humoral Response of Emergency Unit Healthcare Workers after Third Dose of COVID-19 Vaccination\",\"authors\":\"Abror Irsan, Mardhia Mardhia, Ambar Rialita\",\"doi\":\"10.24853/mmj.3.1.27-32\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an emerging disease that has become pandemic. Healthcare workers are vulnerable persons due to SARS-CoV-2 infection. Healthcare workers are a government priority in the COVID-19 vaccine program. Antibody titer evaluation to healthcare workers as the first liner is essential due to the risk of the job. Purposes: The study aims to assess IgG antibody humoral response in healthcare workers in the emergency unit of Anton Soedjarwo Hospital, Pontianak, before and after the third dose of the COVID-19 vaccine. Methods: This study was a descriptive study with a cohort method. Twenty-two healthcare workers in the Emergency Unit in Anton Soedjarwo Hospital, Pontianak, participated in the study. Three ml venous blood samples were collected from the participants in two periods to quantify IgG antibody titer. The first period was before the third dose of the COVID-19 vaccine, and the second period was one month after the third dose of the COVID-19 vaccine. Chemiluminescent Microparticle Immunoassay (CMIA) methods were used to quantification IgG antibodies against spike-receptor binding domain (S-RBD) protein of SARS-CoV-2 Results: One month before the third dose of the COVID-19 vaccine, the majority of IgG antibodies show seropositivity (90.91%), with most on range 50-10,000 AU/ml (54.55%). Two participants (9.09%) show IgG antibodies less than 50 AU/ml (seronegative). One month after the third vaccination dose, all participants (100%) elicit IgG antibodies. Based on the comparison of IgG antibody titer before and after the third dose of the vaccine, the majority (68.18%) showed increasing the IgG antibody titer after the third vaccine. Conclusion: The third dose vaccine might effectively elevate immune response to SARS-CoV-2 infection.\",\"PeriodicalId\":32215,\"journal\":{\"name\":\"Journal of Muhammadiyah Medical Laboratory Technologist\",\"volume\":\"47 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Muhammadiyah Medical Laboratory Technologist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24853/mmj.3.1.27-32\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Muhammadiyah Medical Laboratory Technologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24853/mmj.3.1.27-32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
背景:由严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)引起的冠状病毒病2019 (COVID-19)是一种新兴疾病,已成为大流行疾病。医护人员是SARS-CoV-2感染的易感人群。在COVID-19疫苗项目中,医护人员是政府优先考虑的对象。鉴于工作的危险性,对医护人员进行抗体滴度评估是必不可少的。目的:本研究旨在评估Pontianak Anton Soedjarwo医院急诊科医护人员在第三剂COVID-19疫苗接种前后的IgG抗体体液反应。方法:采用队列法进行描述性研究。Pontianak Anton Soedjarwo医院急诊科的22名医护人员参加了这项研究。分两期采集受试者静脉血3 ml,定量IgG抗体滴度。第一个时期为第三剂疫苗接种前,第二个时期为第三剂疫苗接种后一个月。采用化学发光微粒免疫分析法(CMIA)对新冠病毒棘突受体结合域(S-RBD)蛋白IgG抗体进行定量分析。结果:在第三次疫苗接种前1个月,大多数IgG抗体呈血清阳性(90.91%),阳性范围在50 ~ 10000 AU/ml之间(54.55%)。2例(9.09%)IgG抗体低于50 AU/ml(血清阴性)。在第三次接种后一个月,所有参与者(100%)均产生IgG抗体。比较第三次接种前后IgG抗体滴度,多数(68.18%)在第三次接种后IgG抗体滴度升高。结论:第三剂疫苗可有效提高对SARS-CoV-2感染的免疫应答。
Evaluation of Humoral Response of Emergency Unit Healthcare Workers after Third Dose of COVID-19 Vaccination
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an emerging disease that has become pandemic. Healthcare workers are vulnerable persons due to SARS-CoV-2 infection. Healthcare workers are a government priority in the COVID-19 vaccine program. Antibody titer evaluation to healthcare workers as the first liner is essential due to the risk of the job. Purposes: The study aims to assess IgG antibody humoral response in healthcare workers in the emergency unit of Anton Soedjarwo Hospital, Pontianak, before and after the third dose of the COVID-19 vaccine. Methods: This study was a descriptive study with a cohort method. Twenty-two healthcare workers in the Emergency Unit in Anton Soedjarwo Hospital, Pontianak, participated in the study. Three ml venous blood samples were collected from the participants in two periods to quantify IgG antibody titer. The first period was before the third dose of the COVID-19 vaccine, and the second period was one month after the third dose of the COVID-19 vaccine. Chemiluminescent Microparticle Immunoassay (CMIA) methods were used to quantification IgG antibodies against spike-receptor binding domain (S-RBD) protein of SARS-CoV-2 Results: One month before the third dose of the COVID-19 vaccine, the majority of IgG antibodies show seropositivity (90.91%), with most on range 50-10,000 AU/ml (54.55%). Two participants (9.09%) show IgG antibodies less than 50 AU/ml (seronegative). One month after the third vaccination dose, all participants (100%) elicit IgG antibodies. Based on the comparison of IgG antibody titer before and after the third dose of the vaccine, the majority (68.18%) showed increasing the IgG antibody titer after the third vaccine. Conclusion: The third dose vaccine might effectively elevate immune response to SARS-CoV-2 infection.